NRC Stock Chart & Stats
€1.54
€0.03(1.62%)
At close: 4:00 PM EDT
€1.54
€0.03(1.62%)
Day’s Range― - ―
52-Week Range€0.98 - €3.09
Previous CloseN/A
Volume0.00
Average Volume (3M)20.00
Market Cap
€188.70M
Enterprise Value€160.20
Total Cash (Recent Filing)€19.43M
Total Debt (Recent Filing)€86.52M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Nov 10, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding76,197,220
10 Day Avg. Volume60
30 Day Avg. Volume20
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.07
Price to Sales (P/S)0.61
P/FCF Ratio-4.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.32Price Target Upside180.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.41
Revenue Forecast (FY)€141.18M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRapid top-line expansion, led by Greenbrook, indicates stronger adoption of the company’s neurohealth platform. Sustained clinic growth can increase treatment volume, recurring service demand, and the installed base over the next several quarters.
Improving Margins And Cost DisciplineHigher gross margin and lower operating expenses demonstrate tangible progress toward operating leverage. If mix, pricing, and cost controls persist, these improvements can reduce losses and support a more durable path toward positive cash generation.
Expanded NeuroStar Commercial ModelOffering multiple purchasing and financing structures broadens access to NeuroStar and may reduce upfront barriers for providers. A larger installed base can create recurring consumables and support revenue, although execution remains important during the transition.
Bears Say
Persistent Losses And Negative Cash FlowThe company has not yet converted revenue growth into sustainable cash generation. Continued operating and investing cash use may require additional financing, limiting strategic flexibility and increasing execution risk until operations consistently fund the business.
High Financial LeverageHigh leverage leaves Neuronetics more exposed to refinancing needs and reduces its ability to absorb operational setbacks. The balance sheet therefore places greater importance on achieving sustained profitability and cash generation to stabilize capitalization.
NeuroStar Transition And Clinic UnderutilizationDeclining session utilization and substantial unused clinic capacity constrain recurring treatment revenue and fixed-cost absorption. The shift toward purchase and lease models also creates execution and comparability risks while the company establishes a sustainable commercial mix.
Neuronetics News
NRC FAQ
What was Neuronetics Inc’s price range in the past 12 months?
Neuronetics Inc lowest stock price was €0.98 and its highest was €3.08 in the past 12 months.
What is Neuronetics Inc’s market cap?
Neuronetics Inc’s market cap is €188.70M.
When is Neuronetics Inc’s upcoming earnings report date?
Neuronetics Inc’s upcoming earnings report date is Nov 10, 2026 which is in 75 days.
How were Neuronetics Inc’s earnings last quarter?
Neuronetics Inc released its earnings results on Aug 11, 2026. The company reported -€0.043 earnings per share for the quarter, beating the consensus estimate of -€0.107 by €0.063.
Is Neuronetics Inc overvalued?
According to Wall Street analysts Neuronetics Inc’s price is currently Undervalued.
Does Neuronetics Inc pay dividends?
Neuronetics Inc does not currently pay dividends.
What is Neuronetics Inc’s EPS estimate?
Neuronetics Inc’s EPS estimate is -0.08.
How many shares outstanding does Neuronetics Inc have?
Neuronetics Inc has 76,197,220 shares outstanding.
What happened to Neuronetics Inc’s price movement after its last earnings report?
Neuronetics Inc reported an EPS of -€0.043 in its last earnings report, beating expectations of -€0.107. Following the earnings report the stock price went up 34.545%.
Which hedge fund is a major shareholder of Neuronetics Inc?
Currently, no hedge funds are holding shares in DE:NRC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neuronetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€4.32 (180.44% Upside)
€4.32 (180.44% Upside)
Blogger Sentiment
Bullish
DE:NRC Sentiment 67%
Sector Average 61%
Sector Average 61%
Insider Transactions
Bought Shares
Worth €37.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-61.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.32%
Trailing 12-Months
Company Description
Neuronetics Inc
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
NRC Company Deck
NRC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed measurable operational and financial progress: revenue growth (9.1%), strong Greenbrook performance (+16.8%), margin expansion (to 51.1%), reduced OPEX (-12%), an improved net loss and a positive adjusted EBITDA, plus strengthened cash and an ATM raise. These positives were balanced against execution and timing risks centered on NeuroStar's transition (NeuroStar revenue down 2.7% and sessions down double digits due to inventory normalization and mix shifts), underused clinic capacity (~40%), potential short-term revenue choppiness as customers migrate to new purchase/lease models, and dependence on external regulatory timelines for psychedelics. On balance, the company demonstrated tangible progress toward profitability and cash generation while acknowledging near-term mix and execution challenges.View all DE:NRC earnings summariesNRC Stock 12 Month Forecast
Average Price Target
€4.32
▲(180.44% Upside)